AZ CEO provides update on halted COVID-19 vaccine
trial
AstraZeneca disclosed that a female participant in its UK trial
experienced symptoms of transverse myelitis, a rare and serious spinal
inflammatory disorder, which made the company decide to halt its global Phase
III trials for its investigational COVID-19 vaccine after the board overseeing
the trial's data and safety components confirmed that the woman had been
injected with its vaccine. The woman's diagnosis has yet to be confirmed, but
her condition is reportedly improving and she could be discharged from the
hospital soon, according to AstraZeneca CEO Pascal Soriot.
Full Story: STAT
(tiered subscription model) (9/9)
No comments:
Post a Comment